Zobrazeno 1 - 6
of 6
pro vyhledávání: '"L. Balarini"'
Autor:
R. Chakr, M. Bredemeier, A. Duarte, M. Pinheiro, B. Stadler, J. C. Macieira, R. Ranza, J. Miranda, V. Valim, G. Castro, M. Bertolo, M. D. F. Sauma, V. Fernandes, A. C. Medeiros-Ribeiro, R. Botelho, C. Brenol, H. M. Da Silveira De Carvalho, S. Studart, G. Da Rocha Castelar Pinheiro, L. Rocha, I. Pereira, H. De Leon de Lima, M. Ohira Gazzeta, A. Kakehasi, P. Louzada, A. L. S. Hayata, F. Pina, C. Lupo, L. Balarini, I. Silveira, S. Schowalski, D. Titton, A. Ranzolin, I. Laurindo, R. Xavier
Publikováno v:
Annals of the Rheumatic Diseases. 81:596.2-597
BackgroundThe effect of age on persistence and safety of treatment with biologic disease modifying anti-rheumatic drugs (bDMARDs) in rheumatoid arthritis has been a subject to research interest. Two recently published studies did not observe signific
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::db6af5613ed73ce4ed7201a921fa6faa
https://doi.org/10.1136/annrheumdis-2022-eular.2706
https://doi.org/10.1136/annrheumdis-2022-eular.2706
Autor:
M. Bredemeier, A. Duarte, M. Pinheiro, B. Stadler, J. C. Macieira, R. Ranza, J. Miranda, V. Valim, G. Castro, M. Bertolo, M. D. F. Sauma, V. Fernandes, A. C. Medeiros-Ribeiro, R. Botelho, C. Brenol, H. M. Da Silveira DE Carvalho, S. Studart, G. Da Rocha Castelar Pinheiro, L. Rocha, H. De Leon de Lima, I. Pereira, M. Ohira Gazzeta, A. Kakehasi, P. Louzada, A. L. S. Hayata, F. Pina, M. Alves Ferreira, L. Balarini, I. G. Silveira, S. Kowalski, D. Titton, R. Mendonça Da Silva Chakr, A. Ranzolin, I. Laurindo, R. Xavier
Publikováno v:
Annals of the Rheumatic Diseases. 81:360.2-361
BackgroundAntimalarials (AM) are frequently part of the initial scheme of conventional synthetic DMARDs in the treatment of rheumatoid arthritis (RA), and have been associated with lower incidence of diabetes and better lipid profile in these patient
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1ceb18110f322c04db0a32d4ddf73805
https://doi.org/10.1136/annrheumdis-2022-eular.4120
https://doi.org/10.1136/annrheumdis-2022-eular.4120
Autor:
S. M M de Souza, A. C. Medeiros-Ribeiro, M. Bredemeier, A. Duarte, M. Pinheiro, B. Stadler, J. C. Macieira, R. Ranza, J. Miranda, V. Valim, G. Castro, M. Bertolo, M. D. F. Sauma, V. Fernandes, R. Botelho, C. Brenol, H. M. Da Silveira DE Carvalho, S. Studart, G. Da Rocha Castelar Pinheiro, L. Rocha, H. De Leon de Lima, I. Pereira, M. Ohira Gazzeta, A. Kakehasi, P. Louzada, A. L. S. Hayata, F. Pina, M. Alves Ferreira, L. Balarini, I. G. Silveira, S. Kowalski, D. Titton, R. Mendonça Da Silva Chakr, A. Ranzolin, I. Laurindo, R. Xavier
Publikováno v:
Annals of the Rheumatic Diseases. 81:1701.3-1702
BackgroundThe SARS-CoV-2 virus has caused a worldwide health crisis. Patients with inflammatory arthritis are at higher risk of hospitalization and death by COVID-19 due to comorbidities or immunosuppressive treatments. Vaccination is one the most im
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d9870f5ed931b4376d32fb010ace9fcd
https://doi.org/10.1136/annrheumdis-2022-eular.4722
https://doi.org/10.1136/annrheumdis-2022-eular.4722
Autor:
D. Negrão Gonçalo Dias, D. Titton, R. Xavier, G.da R.C. Pinheiro, M. Pinheiro, Ieda Maria Magalhães Laurindo, L. Balarini, José Caetano Macieira, Fabiana Pompeo de Pina, Manoel Barros Bertolo, M. Ohira Gazzeta, Markus Bredemeier, Cristiano Michelini Lupo, Roberto Ranza, Valeria Valim, P. Louzada, A. Maria Kakehasi, Lívia G. Rocha, Claiton Viegas Brenol, Vander Fernandes, Maria de Fátima Lobato da Cunha Sauma, S. Studart, R Botelho, Hellen M.S. Carvalho, Ana Paula Medeiros, Ivânio Alves Pereira, Gláucio Ricardo Werner de Castro, Inês Guimarães da Silveira, João Luiz de Miranda, Aline Ranzolin, B. Stadler, Sergio Kowalski, A. Duarte, André Luiz Shinji Hayata, R. Chakr
Publikováno v:
Annals of the Rheumatic Diseases. 80:582.2-583
Background:After failure of conventional synthetic disease modifying anti-rheumatic drugs (csDMARDs) in the therapy of rheumatoid arthritis (RA), treatment may be escalated to biologic (bDMARDs) or JAK inhibitors (JAKi) (1). Analysis of drug survival
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::80ede3938828b2943eb873edc00b27b9
https://doi.org/10.1136/annrheumdis-2021-eular.3841
https://doi.org/10.1136/annrheumdis-2021-eular.3841
Autor:
K.L.L. Lira, L. Balarini, S.M.B. De Lima, A.C.C. Azevedo, A.T. De Carvalho, V.P.M. Paschoal, S.T. Myiamoto, A.L.S. De Souza, P.C.M. Rocha, T. Zanon, E.V. Serrano, R.H. Duque, M.B.R.O. Gavi, V. Dinis, L.C. Caser, F. Salume, A. Dalmaso, A.P. Burian, L.F. Pinto, null Brandão, E. Polito, T.B. Clemente, E.S. Magalhaes, L.C. Rodrigues, F. Morello, K.G. De Oliveira, M.M. Thebit, M.F. Bissoli, S.A. Gouvea, O. Assis, L.D.M. De Moura, V. Valim
Publikováno v:
Revista Brasileira de Reumatologia. 57:S69
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9274ad391adc0db33245f589103d30e8
https://doi.org/10.1016/j.rbr.2017.06.119
https://doi.org/10.1016/j.rbr.2017.06.119
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.